tapinarof
Sponsor Organon & CO. · listed as OGN
tapinarof is a drug asset sponsored by Organon & CO., listed as OGN. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Oct 2026 (month precision, medium confidence), tied to trial NCT05172726. That trial is in Phase 3 and currently active not recruiting, studying Plaque Psoriasis. It appears across 2 tracked trials in the CSA sample.
Next catalyst
Trial & sponsor
Trials for tapinarof in the CSA sample
| Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|
| NCT05172726 catalyst | Phase 3 | Active, not recruiting | 2026-10 | Experimental | Organon and Co | Plaque Psoriasis |
| NCT05981118 | Phase 2/3 | Enrolling by invitation | 2027-01 | Active comparator | Wake Forest University Health Sciences | ICD10 Code L40.9 for Psoriasis |
Each trial links to its ClinicalTrials.gov record; primary completion dates are as registered there.
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This page is one record from the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 → More OGN catalysts